Meeting
2017 Gastrointestinal Cancers Symposium
Phase I study of gemcitabine (G), dasatinib (D), and erlotinib (E) in advanced pancreatic carcinoma (PC).
Authors
Dana Backlund Cardin
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
Dana Backlund Cardin , Laura Williams Goff , Emily Chan , Jennifer Whisenant , Lori R. Arlinghaus , Thomas Yankeelov , Tatsuki Koyama , Jordan Berlin , Nipun B. Merchant
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01660971
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 315)
DOI
10.1200/JCO.2017.35.4_suppl.315
Abstract #
315
Poster Bd #
E7
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
First Author: David Bing Zhen
Poster
2014 ASCO Annual Meeting
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
First Author: Manish Sharma
Poster
2013 Gastrointestinal Cancers Symposium
A phase I study of hyperfractionated low-dose radiotherapy (RT) as a chemotherapy sensitizer in combination with gemcitabine (G) and erlobtinib (E) in advanced pancreatic cancer.
First Author: Andre Konski
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca